![Aaron Tward](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Aaron Tward
Technik-/Wissenschafts-/F&E-Leiter bei
AKOUOS
Profil
Aaron Tward is the founder of Affinia Therapeutics, Inc., founded in 2019.
Dr. Tward currently holds the positions of Associate Professor at The University of California, San Francisco since 2022 and Chief Scientific Officer at Akouos, Inc. since 2022.
Dr. Tward earned a doctorate degree from The University of California, San Francisco.
Aktive Positionen von Aaron Tward
| Unternehmen | Position | Beginn |
|---|---|---|
| AKOUOS | Technik-/Wissenschafts-/F&E-Leiter | 10.03.2022 |
The University of California, San Francisco
 The University of California, San Francisco Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | 01.03.2022 |
Ehemalige bekannte Positionen von Aaron Tward
| Unternehmen | Position | Ende |
|---|---|---|
Affinia Therapeutics, Inc.
 Affinia Therapeutics, Inc. BiotechnologyHealth Technology Develops adeno-associated virus gene therapies | Gründer | - |
Ausbildung von Aaron Tward
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
68
Beziehungen ersten Grades
3
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 3 |
|---|---|
The University of California, San Francisco
The University of California, San Francisco Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Akouos, Inc.
 Akouos, Inc. Miscellaneous Commercial ServicesCommercial Services Operates as a genetic medicine company that develops adeno-associated viral vector-based gene therapies for sensorineural hearing loss | Commercial Services |
Affinia Therapeutics, Inc.
Affinia Therapeutics, Inc. BiotechnologyHealth Technology Develops adeno-associated virus gene therapies | Health Technology |
